Pioneers in Immunoregulatory Drug Discovery and Development
We develop novel immunoregulatory therapeutics for patients with autoimmune diseases, starting with ulcerative colitis and Crohn’s disease.
Our Mission
We are a late-clinical-stage precision immunology biopharmaceutical company focused on the development of best-in-class biomarker-driven immunoregulatory therapeutics. Our lead clinical candidate, omilancor, is a Phase 3-ready, first-in-class, oral, gut-restricted LANCL2 agonist for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD).
Our management team has significant experience in development of immunoregulatory drugs and a proven track record of effectively accelerating drug candidates into and through late-stage clinical development. We are on a mission to develop safer and more effective therapeutics that address the unmet needs of patients with autoimmune diseases.
Press and Articles from NImmune
NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease
Approvable population of ulcerative colitis (UC) patients for upcoming Phase 3 trials agreed upon with the U.S. Food and Drug Administration (FDA) Analysis of Phase 2 data using approvable UC patient population for Phase 3 demonstrated statistical significance in...
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline
Provides NImmune access to NIMML’s TITAN-X advanced computational modeling and A.I. platform to accelerate biomarker-driven clinical development of its LANCL immunoregulatory drug pipeline NImmune will commit up to $15 million in R&D funding for the precision...
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms
Inflammatory bowel disease (IBD) afflicts 5 million people and is increasing in prevalence. There is an unmet clinical need for safer and effective treatments for IBD. The BT-11 is a small molecule oral therapeutic that ameliorates IBD by targeting lanthionine...
NImmune Leadership Team
A highly experienced and talented team with deep knowledge of LANCL therapeutics and a proven track record of biotech industry success.
Product Candidates
NImmune’s clinical development pipeline includes best-in-class biomarker-driven immunoregulatory therapeutics for autoimmune diseases with multiple catalyst milestones. Lead clinical candidate omilancor, a Phase 3-ready immunoregulatory therapeutic targeting LANCL2, is an oral, once-daily, gut-restricted, first-in-class therapeutic for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2023 with data readout in 12-18 months.
Learn more about the omilancor story, LANCL2 mechanism of action, and the market opportunity we seek to address.
Contact Us
If you would like to know more about our research, please fill out the form below.